Atypical antipsychotics are described as 'second generation' because they were developed to add to the effectiveness of first generation medications, and also alleviate the serious side effects associated with such drugs.
Atypical antipsychotics work in the same way as typical antipsychotics, but also target other neurotransmitter receptors on postsynaptic membranes, in line with more modern research. For example, Clozapine targets serotonin and glutamate receptors, whilst Risperidone acts on dopamine and serotonin receptors.